Arctic Bioscience

Arctic Bioscience - Share capital increase registered

Reference is made to the stock exchange release published by Arctic Bioscience

12th December 2025 regarding Board approval of share capital increase related to

the exercise of debt conversion rights and corresponding issuance of new shares

in Arctic Bioscience.

The share capital increase has now been registered with the Norwegian Register

of Business Enterprises. As a result, the new share capital of Arctic Bioscience

has increased from NOK 2 685 934 to NOK 2 695 625,60, divided into 26 956 256

shares, each having a nominal value of NOK 0,10.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI Terminal